For immediate release |
28 February 2013 |
ANGLE plc
("ANGLE" or "the Company")
PARSORTIX RESEARCH PRODUCT LAUNCH
ANGLE plc (AIM: AGL), the specialist medtech company, is pleased to announce that the Company has initiated the launch of its Parsortix non-invasive cancer diagnostic product for the research market.
Depending on user requirements, the Parsortix system, which is based on a simple blood test, can be configured either for the counting and identification of circulating tumour cells (CTCs) in the blood or for the capture and recovery (harvesting) of CTCs from the blood as a "liquid biopsy" for molecular analysis of the cells.
To accelerate deployment of the Parsortix system, ANGLE is in the process of placing machines on loan with a limited number of key users worldwide. The key users' research work will contribute to the data sets that Parsortix is developing to support regulatory submissions for CE marking and FDA approval. The key users will also be important as opinion leaders for the acceptance of the product in the clinical market.
The Company's existing research partners, the Paterson Institute for Cancer Research and the University of Surrey's Oncology Department, are continuing to use the Parsortix system successfully.
ANGLE's Founder and Chief Executive, Andrew Newland, commented:
"Launch of the Parsortix system in the research market is a key milestone moving the business from the development stage into commercialisation. We are now intending to move rapidly to establish some key collaborations with leading cancer research groups."
For further information:
ANGLE plc |
01483 685830 |
Andrew Newland, Chief Executive Ian Griffiths, Finance Director |
|
Cenkos Securities Stephen Keys, Adrian Hargrave (Nominated adviser) Andy Roberts, Christian Hobart (Sales) |
020 7397 8900 |
Buchanan Mark Court, Fiona Henson, Sophie Cowles |
020 7466 5000 |
|
|
